A 54-year-old woman developed euthyroid sick syndrome (ESS) after losing 22 kilograms over four months on semaglutide, presenting with fatigue, lethargy, and cold intolerance. Laboratory tests showed the classic ESS pattern: low free T3, low-normal free T4, and inappropriately normal TSH levels, occurring without underlying thyroid disease. This case illuminates an underrecognized consequence of GLP-1 receptor agonist therapy that's becoming increasingly relevant as these medications gain widespread adoption for weight management. ESS represents the body's adaptive response to metabolic stress, where peripheral tissues reduce thyroid hormone conversion to conserve energy during rapid weight loss. The mechanism involves decreased conversion of T4 to the active T3 hormone, essentially putting the body into a lower metabolic state. While this adaptation may be physiologically protective during periods of metabolic stress, it creates a clinical paradox: patients using semaglutide for metabolic benefits may experience thyroid-like symptoms that could be mistaken for thyroid disease. This finding suggests clinicians should monitor thyroid function differently in patients on GLP-1 therapies, recognizing that ESS may be a normal physiological response rather than pathology requiring treatment.